항혈소판제: 프로스타글란딘 합성, P2Y12 및 당단백질 IIb/IIIa 억제제

The three main types of antiplatelet drugs are prostaglandin synthesis inhibitors, P2Y12 inhibitors, and glycoprotein IIb/IIIa inhibitors. Prostaglandin synthesis inhibitors like aspirin irreversibly acetylate the COX I enzyme to inhibit thromboxane A2 synthesis. P2Y12 inhibitors such as clopidogrel block the ADP-binding receptor on platelets. Glycoprotein IIb/IIIa inhibitors like abciximab prevent platelet aggregation by blocking their target receptor.

Aspirin works by irreversibly acetylating the COX I enzyme, which inhibits its activity in synthesizing thromboxane A2, a potent platelet activator. By blocking thromboxane A2 production, aspirin prevents platelet activation and aggregation, reducing clot formation. This mechanism makes aspirin effective at preventing thromboembolic diseases like myocardial infarction and thrombotic stroke.

P2Y12 inhibitors such as clopidogrel, ticagrelor, and prasugrel block the ADP-binding P2Y12 receptor on the platelet surface. This blockade inhibits platelet activation and aggregation at the source, preventing dangerous clots from forming. By targeting this specific receptor, these drugs effectively reduce the risk of thromboembolic events.

Glycoprotein IIb/IIIa inhibitors such as abciximab, eptifibatide, and tirofiban block the glycoprotein IIb/IIIa receptor on platelets. This strategic blockade prevents platelet aggregation at its core, rendering clots powerless to form. These drugs are particularly effective at stopping the final common pathway of platelet clumping.

Antiplatelet drugs prevent and manage thromboembolic diseases where abnormal clots obstruct blood vessels. They reduce the risk of potentially life-threatening conditions including myocardial infarction, coronary artery disease, and thrombotic stroke. By inhibiting platelet aggregation and clot formation, these drugs safeguard cardiovascular health.

Common side effects of antiplatelet drugs include bleeding, nausea, and vomiting. These adverse reactions underscore the delicate balance between therapeutic intervention and potential risks. Careful medical supervision is crucial in optimizing the benefits of these drugs while managing their associated side effects.

Antiplatelet drugs inhibit platelet aggregation and clot formation through receptor blockade or enzyme inhibition, while anticoagulant drugs work through different mechanisms. Antiplatelet drugs target platelet function directly, whereas anticoagulant drugs vitamin antagonists and direct oral anticoagulants affect the coagulation cascade. Both classes prevent thromboembolic disease but through distinct pharmacological pathways.